Selinexor, Bortezomib, and Dexamethasone for Heavily Pretreated Multiple Myeloma: A Case Series

被引：5
|
作者：
Magen, Hila [1 ,2 ]
Geva, Mika [1 ,2 ]
Volchik, Yulia [1 ]
Avigdor, Abraham [1 ,2 ]
Nagler, Arnon [1 ,2 ]
机构：
[1] Chaim Sheba Med Ctr, Div Hematol & Bone Marrow Transplantat, Dept Hematol, Ramat Gan, Israel
[2] Tel Aviv Univ, Sackler Fac Med, Tel Aviv, Israel
来源：
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2020年 / 20卷 / 12期
关键词：
Heavily treated patients; Hematologic malignancies; Relapsing/refractory multiple myeloma; Selective inhibitor of nuclear export; Treatment response; TOPOISOMERASE-II; ORAL SELINEXOR; NUCLEAR EXPORT; INHIBITION; DIAGNOSIS; CRITERIA; CELLS;
D O I：
10.1016/j.clml.2020.07.016
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
[No abstract available]
引用
收藏
页码：E947 / E955
页数：9
相关论文
共 50 条
  • [41] A real-world study of panobinostat, weekly bortezomib and dexamethasone in a very heavily pretreated population of multiple-myeloma patients
    Bird, Sarah
    Pawlyn, Charlotte
    Nallamilli, Susanna
    Sriskandarajah, Priya
    Kaiser, Martin
    Yong, Kwee
    Popat, Rakesh
    Rabin, Neil
    Boyd, Kevin
    BRITISH JOURNAL OF HAEMATOLOGY, 2020, 191 (05) : 927 - 930
  • [42] Selinexor plus low-dose bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma
    Bahlis, Nizar J.
    Sutherland, Heather
    White, Darrell
    Sebag, Michael
    Lentzsch, Suzanne
    Kotb, Rami
    Venner, Christopher P.
    Gasparetto, Cristina
    Del Col, Aldo
    Neri, Paola
    Reece, Donna
    Kauffman, Michael
    Shacham, Sharon
    Unger, T. J.
    Jeha, Jacqueline
    Saint-Martin, Jean-Richard
    Shah, Jatin
    Chen, Christine
    BLOOD, 2018, 132 (24) : 2546 - 2554
  • [43] US Budget Impact Model for Selinexor, Bortezomib, and Dexamethasone for the Treatment of Previously Treated Multiple Myeloma
    Dolph, Mike
    Tremblay, Gabriel
    Leong, Hoyee
    CLINICOECONOMICS AND OUTCOMES RESEARCH, 2021, 13 : 493 - 502
  • [44] Selinexor combined with bortezomib, lenalidomide, and dexamethasone for the treatment of newly diagnosed multiple myeloma with extramedullary disease
    Yin, Junjing
    Zhou, Xia
    Li, Xuemei
    Yuan, Chenglu
    Chu, Xiaoxia
    Hao, Lumei
    Wu, Hongying
    Zhong, Yuping
    SCIENTIFIC REPORTS, 2024, 14 (01):
  • [45] Selinexor-dexamethasone for refractory multiple myeloma
    Stirrups, Robert
    LANCET ONCOLOGY, 2019, 20 (10): : E560 - E560
  • [46] Pomalidomide in heavily pretreated refractory multiple myeloma: a case report
    Palmas, Angelo
    Piras, Giovanna
    Uras, Antonella
    Asproni, Rosanna
    Murineddu, Marco
    Monne, Maria
    Stradoni, Roberta
    Latte, Giancarlo
    FUTURE ONCOLOGY, 2017, 13 (05) : 7 - 9
  • [47] Cost-effectiveness of once-weekly selinexor, bortezomib, and dexamethasone in relapsed or refractory multiple myeloma
    Patel, Kishan K.
    Parker, Terri
    Di, Mengyang
    Bar, Noffar
    Huntington, Scott F.
    Giri, Smith
    LEUKEMIA & LYMPHOMA, 2021, 62 (11) : 2777 - 2784
  • [48] Pomalidomide, Bortezomib, and Dexamethasone in Lenalidomide-Pretreated Multiple Myeloma: A Subanalysis of OPTIMISMM by Frailty and Bortezomib Dose Adjustment
    Oriol, Albert
    Dimopoulos, Meletios
    Schjesvold, Fredrik
    Beksac, Meral
    Facon, Thierry
    Dhanasiri, Sujith
    Guo, Shien
    Mu, Yutian
    Hong, Kevin
    Gentili, Christian
    Galli, Monica
    Yagci, Munci
    Larocca, Alessandra
    Richardson, Paul
    Weisel, Katja
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 (03): : 165 - 176.e4
  • [49] Bortezomib and dexamethasone induction for multiple myeloma
    Jacob Laubach
    Paul Richardson
    Nature Reviews Clinical Oncology, 2011, 8 : 8 - 10
  • [50] Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma
    Palumbo, Antonio
    Chanan-Khan, Asher
    Weisel, Katja
    Nooka, Ajay K.
    Masszi, Tamas
    Beksac, Meral
    Spicka, Ivan
    Hungria, Vania
    Munder, Markus
    Mateos, Maria V.
    Mark, Tomer M.
    Qi, Ming
    Schecter, Jordan
    Amin, Himal
    Qin, Xiang
    Deraedt, William
    Ahmadi, Tahamtan
    Spencer, Andrew
    Sonneveld, Pieter
    NEW ENGLAND JOURNAL OF MEDICINE, 2016, 375 (08): : 754 - 766
12345